The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

December 7, 2021 • By Jeffrey Curtis, MD, MS, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Abstract 0455: Abatacept reverses subclinical arthritis in patients with high-risk to develop rheumatoid arthritis—Results from the randomized, placebo-controlled ARIAA study in RA-at risk patients6

You Might Also Like
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
Explore This Issue
January 2022
Research by Rech J, et al.

Given the potential for antibodies against citrullinated proteins (ACPA) to herald a sooner transition to manifest RA, the opportunity to abrogate or slow that progression may invite therapeutic intervention.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients who were ACPA positive with MRI signs of inflammation were randomized to receive subcutaneous abatacept for six months. Arthritis developed at a higher frequency of patients receiving placebo (34.7%) compared with those receiving abatacept (8.2%, P=0.0025).

Although some may argue that ACPA positivity and MRI-observed synovitis represent the forme fruste of RA, the potential benefit of abatacept to improve subclinical arthritis supports the concept that early intervention with abatacept may prevent, or at least delay, the development of RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

COVID-19

COVID-19 continues to capture the attention of rheumatologists and patients alike. Although rituximab has been repeatedly recognized to be associated with a suboptimal response to COVID-19 vaccination, perhaps warranting a supplemental vaccine dose, the impact of other RA therapies on COVID-19 vaccination is less clear.

Abstract L02: COVID-19 vaccine in immunosuppressed adults with autoimmune diseases7

Research by Colmegna I, et al.

Results from this prospective, open label trial at two centers in Quebec of patients with seropositive RA on stable treatment for at least three months found that on average, patients with RA did not have significant side effects or disease worsening (i.e., flare) after vaccination. As observed previously, immunogenicity, measured by anti-spike antibodies and antibodies against its receptor binding domain, was poor in rituximab-treated patients (Note: Only 17.6% of patients responded after the second dose) and was numerically lower (i.e., 88%) in JAK inhibitor-treated patients. Biologic-treated patients had a robust immunogenicity in this study, although the response to specific biologic agents was not reported.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

This study adds to growing evidence that COVID-19 vaccination is safe and generally well tolerated in patients with RA or other autoimmune diseases, albeit with some small risk for adverse events or flare. It also raises some concerns that other immunomodulators, such as JAK inhibitors, may attenuate COVID-19 vaccine response.

Abstract L18: Humoral and cellular immune responses to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: A cohort study8

Research by Mahil SK, et al.

Because immunomodulatory agents have potentially important implications on vaccine response for patients for RA or other disease indications (e.g., psoriasis, psoriatic arthritis), new data were presented on the influence of methotrexate (MTX). Patients with psoriasis (n=82) receiving MTX (n=14) or TNF inhibitors (n=19) all were shown to have seroconverted after the second vaccine dose. However, detectable T cell responses were lower in MTX-treated patients (62%, 95%CI 32–86) or targeted biologic users (74%, 95% CI 60–85%) compared with healthy controls (100%, P=0.022).

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Research Reviews, Rheumatoid Arthritis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RAIssue: January 2022

You Might Also Like:
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)